Drug Licence and Statutory Requirements for Ayurvedic Medicine Distributors in India
Operating as an Ayurvedic medicine distributor in India requires more than a supply agreement with a manufacturer. Several statutory licences and registrations must be in place before the first invoice is raised — and each carries ongoing compliance obligations that, if neglected, can halt operations faster than any commercial setback.
This guide covers the four main licence categories, the five-step process for obtaining and maintaining statutory compliance, the operating disciplines that prevent licence lapses, and the most common mistakes that result in regulatory disruption.
Four Statutory Licence Categories for Ayurvedic Distributors
The specific licences required depend on the products in the portfolio, the state of operation, and the scale of the business. The four categories below apply to the majority of B2B Ayurvedic medicine distributors operating across India:
| Licence category | Issuing authority | Key requirement | Consequence of lapse |
|---|---|---|---|
| Wholesale Drug Licence (Form 21B) | State Drug Control Authority / State Drug Controller | Valid for wholesale purchase and supply of scheduled Ayurvedic drug products; requires a qualified person (registered pharmacist or BAMS holder), licensed storage premises meeting Good Storage Practice standards, and payment of the prescribed annual fee | Cannot legally purchase or supply scheduled drug products; principal manufacturer cannot supply to an unlicensed dealer; operations halt until licence is reinstated — reinstatement typically requires a fresh premises inspection |
| GST Registration | GST Council / State tax authority via GST portal | Mandatory for B2B distributors with annual turnover above ₹40 lakh (₹20 lakh in some states); generates a GSTIN required for all B2B purchase and sales invoices; monthly or quarterly return filing obligation | Cannot issue GST-compliant invoices; retailers and sub-stockists cannot claim input tax credit on purchases; principal manufacturer may suspend supply to an unregistered dealer; penalties on non-compliant billing accumulate retrospectively |
| Shops and Establishments Act Registration | State Labour Department / Municipal Corporation — varies by state | Mandatory for commercial premises operating in most states; registration is premises-specific; covers labour law compliance, working hours, and commercial premises recognition; annual renewal required in most states | Non-compliance with state commercial law; premises may be flagged during drug inspector or municipal inspection; required for certain banking and commercial account verifications |
| Municipal Trade Licence | Local Municipal Corporation / Gram Panchayat / Urban Local Body | Required by most local bodies for commercial operations within their jurisdiction; annual renewal; premises inspection may be required at the time of first application or on change of premises | Exposure to municipal enforcement action; premises may be sealed pending regularisation; required for commercial address verification and certain statutory filings |
Five-Step Process for Obtaining and Maintaining Statutory Compliance
Licence applications involve state-specific processes that take time. Starting the process before commercial operations begin — not after the first supply agreement is signed — is the standard practice among experienced distributors:
Confirm which products in your portfolio require a drug licence
Not every Ayurvedic product sold in India requires a wholesale drug licence. Products that are classified as scheduled drugs under the Drugs and Cosmetics Act, 1940 — including those in Schedule E1 or containing substances requiring regulatory oversight — require a licenced dealer to purchase and supply them. Before applying for a drug licence, confirm with your principal manufacturer which specific products in the proposed range fall under the scheduled drug category. Manufacturers are typically able to provide this information based on their own regulatory filing records. If the portfolio includes no scheduled products, a drug licence may not be required — but this confirmation should be obtained in writing from the manufacturer's regulatory team, not assumed.
Engage a qualified person before submitting the licence application
A wholesale drug licence application requires the credentials of a qualified person — a registered pharmacist or, in some states for Ayurvedic medicines, a BAMS degree holder. The qualified person must be employed by the distribution firm and available at the licensed premises during business hours. Engaging a qualified person after the licence application has been submitted creates delays because the application cannot be processed without their credentials. Identify, verify, and engage the qualified person as the first step in the licensing process — before any premises have been committed to or any supply agreements have been signed — because the licence terms are linked to both the qualified person's credentials and the specific premises address.
Prepare the storage premises to Good Storage Practice standards before the inspection
Drug licence applications trigger a premises inspection by the State Drug Control Authority. Inspectors assess whether the storage facility meets Good Storage Practice requirements: appropriate temperature and humidity conditions, a designated quarantine area, shelving that keeps stock off the floor, a separate dispatch staging area, a functioning temperature and humidity monitoring system, and a current stock register format. Premises that fail the initial inspection require a second inspection after rectification — which adds weeks to the licensing timeline. Preparing the premises to inspection-ready standard before the application is submitted avoids this delay. The manufacturer's regulatory team or a local drug licence consultant familiar with state-specific inspection requirements can provide a pre-inspection checklist.
Submit all applications simultaneously and track progress actively
Wholesale drug licence, GST registration, Shops and Establishments Act registration, and municipal trade licence applications can typically be submitted in parallel rather than sequentially. GST registration is processed through the online GST portal and is typically the fastest to complete. State drug licence applications involve a manual inspection process and take longer — often 30 to 60 days in most states, sometimes longer depending on the State Drug Control Authority's workload. Municipal and Shops and Establishments registrations vary by local body. Tracking the status of each application actively — rather than waiting to be contacted — and responding promptly to any additional document requests reduces processing delays. Assign a single point of contact within the firm for all statutory applications.
Build an annual renewal calendar and maintain it 90 days in advance
Each licence has its own renewal schedule — drug licences in most states require annual fee payment to remain in good standing (even if the licence itself has a five-year validity), GST registrations do not expire but require ongoing annual return filing, Shops and Establishments Act registrations are typically renewed annually, and municipal trade licences are renewed annually. A licence that lapses because the renewal application was not filed in time creates the same disruption as a new application — premises inspection, processing delay, and potential supply chain gap. Build a calendar with the renewal due date for every statutory licence and registration in the business, set alerts 90 days before each due date, and initiate the renewal process at that point — not at the expiry date. Include the qualified person's professional registration renewal in the same calendar.
Four Disciplines That Prevent Licence Lapses and Inspection Failures
Qualified person continuity — never a single-person dependency
The wholesale drug licence is linked to the qualified person's credentials. If the qualified person resigns, is unavailable for an extended period, or their professional registration lapses, the drug licence is at risk. Distribution businesses that rely on a single qualified person without a documented continuity arrangement are one resignation away from a licence suspension. Practical mitigation includes maintaining a registered backup arrangement with a second qualified person who can be activated if the primary person leaves, and tracking the professional registration renewal dates of the qualified person alongside the firm's own licence renewal calendar.
Premises inspection readiness maintained year-round
Drug inspector visits can occur at any time — they are not always announced in advance. Storage premises should be maintained at inspection-ready standard continuously, not prepared in response to an expected visit. This means temperature and humidity logs updated daily, stock registers reconciled weekly, all stock clearly labelled with batch numbers and expiry dates visible, quarantine area maintained as a designated separate zone, and no unlicensed or misbranded products present in the premises. A distributor who needs several days to get their premises inspection-ready is a distributor whose practices have drifted from GSP compliance.
Licence register maintained with original documents and copies
Maintain a physical or digital register of every statutory licence and registration held by the business, including the licence number, the issuing authority, the validity period, the renewal due date, and the name of the person responsible for managing the renewal. Keep a scanned copy of every licence alongside the original. Drug inspectors and bank officers frequently request licence copies for verification — not having an accessible, current copy of every licence creates unnecessary delays and reflects poorly on the operational discipline of the business. Review the licence register quarterly and update it immediately when any renewal is completed.
Compliance calendar reviewed at the start of every quarter
A compliance calendar that is built once and never reviewed becomes stale. At the start of every quarter, review all upcoming renewal dates and statutory filing deadlines — drug licence fee payment, GST annual return, Shops and Establishments registration renewal, municipal trade licence renewal — and confirm that the responsible person for each has the renewal process in motion where the due date falls within the next 90 days. This quarterly review takes less than 30 minutes and prevents the category of compliance lapse that arises simply because a renewal date was not tracked actively.
Important: not all Ayurvedic products require a drug licence
A common source of confusion is the assumption that distributing any Ayurvedic product automatically requires a wholesale drug licence. This is not accurate. The licence requirement depends on the specific schedule classification of the products in the portfolio under the Drugs and Cosmetics Act. Distributors who assume a licence is required when it is not spend time and money on an unnecessary application. Those who assume a licence is not required when it is expose themselves to regulatory enforcement action. Confirm the schedule classification of every product in the proposed range with the manufacturer's regulatory team — in writing — before committing to a premises or recruiting a qualified person.
Three Benchmarks for Statutory Compliance Discipline
No statutory licence should ever lapse before renewal. A zero-lapse record is the benchmark for compliance discipline — it means every renewal was completed before the prior licence period expired, not after. A single drug licence lapse that halts a supply chain costs far more to recover than the cost of the 90-day renewal process.
Every statutory licence and registration held by the business should be reflected in the licence register with current validity dates, and original documents should be producible on request. A register that is incomplete or out of date creates risk at exactly the moment when an inspector or a bank officer needs to verify a licence — moments when inaccuracy cannot be recovered quickly.
Any statutory licence, registration, or compliance document required by a drug inspector, bank, or trade partner should be producible within seven days — in practice, immediately for digital copies and within one working day for originals. A longer response time signals that licence management is not being actively maintained.
Five Mistakes That Create Regulatory and Operational Disruption
| Mistake | Consequence | Prevention |
|---|---|---|
| Assuming a drug licence is required without confirming the schedule classification of the products | Time and money spent on a drug licence application that may not be required for the specific products in the portfolio, or — in the reverse — operating without a licence that is actually required for certain scheduled products, exposing the business to enforcement action. | Obtain written confirmation from the manufacturer's regulatory team on the schedule classification of every product in the proposed range before initiating any licence application. |
| Beginning commercial operations before the drug licence application is complete | Purchasing or supplying scheduled drug products without a valid wholesale drug licence is a violation of the Drugs and Cosmetics Act. The principal manufacturer is also prohibited from supplying to an unlicensed dealer. Commencing operations before licensing creates retrospective compliance exposure that cannot be easily resolved. | Do not raise the first purchase order or accept the first supply from the manufacturer until the wholesale drug licence application has been submitted and the manufacturer's regulatory team has confirmed that supply can proceed under the pending application. In most states, supply cannot legally commence until the licence is issued. |
| Not maintaining a qualified person appointment as a continuous condition of the licence | A drug licence issued in connection with a qualified person who is no longer employed by the firm — or whose professional registration has lapsed — is a licence condition violation that can result in suspension or cancellation. The manufacturer may also be required to suspend supply to maintain their own compliance. | Track the qualified person's employment status and professional registration renewal date in the same compliance calendar as the drug licence itself. Have a documented continuity arrangement that can be activated if the qualified person leaves. |
| Allowing the drug licence renewal fee payment to lapse | In many states, the drug licence requires annual fee payment to remain in good standing even when the licence itself has a multi-year validity period. A licence that has lapsed due to non-payment of the annual fee is treated as an unlicensed operation — with the same operational and legal consequences as a lapsed licence. | Include the annual drug licence fee payment date in the compliance calendar and treat it as a fixed obligation — like a tax payment — that is processed automatically before the due date each year. |
| Storage premises not maintained at Good Storage Practice standard between inspections | A drug inspector visit to premises that are not meeting GSP requirements — inadequate temperature control, stock commingled without quarantine separation, outdated stock registers, expired stock not segregated — can result in an improvement notice, a licence show-cause, or in serious cases a premises seal order. Rectification after enforcement action is far more disruptive than maintaining standards continuously. | Maintain GSP compliance as a daily operating standard, not as an inspection preparation exercise. Assign a specific person to be responsible for daily temperature and humidity logging, weekly stock register reconciliation, and monthly expiry date checks across all stock. |
Frequently Asked Questions
Does every Ayurvedic medicine distributor in India need a drug licence?
Not every Ayurvedic product requires a drug licence, but the requirement depends on the schedule classification of the products in the portfolio. Ayurvedic medicines that are classified as Schedule E1 drugs under the Drugs and Cosmetics Act, 1940 — or those containing substances that require a prescription — must be purchased and sold only by a licensed wholesale drug dealer. Distributors handling a portfolio that includes any Schedule E1 or similarly classified Ayurvedic products require a valid wholesale drug licence issued by the State Drug Control Authority before they can legally stock, purchase, or supply those products. Distributors should review the schedule classification of every product in their proposed range with their principal before committing to a territory — the manufacturer's regulatory team can typically confirm which products fall under the licenced category.
What is a qualified person for the purpose of a wholesale drug licence?
A qualified person, for the purposes of a wholesale drug licence under the Drugs and Cosmetics Act, is an individual who holds an educational qualification prescribed by the relevant state drug licensing authority — typically a registered pharmacist, a person with a degree in pharmacy, or in some states for Ayurvedic medicines specifically, a holder of a BAMS (Bachelor of Ayurvedic Medicine and Surgery) degree. The qualified person must be in active employment with the distribution firm at the time of licensing and must be present at the licensed premises during business hours. The drug licence is issued in the name of the licensed entity but is linked to the qualified person's credentials. If the qualified person leaves the firm or their registration lapses, the drug licence may be suspended or cancelled pending the appointment of a replacement — which makes continuity of this appointment a critical operational risk to manage actively.
What is the difference between a drug licence under Form 20B and Form 21B?
Form 20B is the application form for a licence to wholesale drugs specified in Schedule C and C1 of the Drugs and Cosmetics Act — which includes biological products, vaccines, and certain regulated pharmaceuticals. Form 21B is the application form for a licence to wholesale other drugs not covered under Form 20B, which includes the broader range of Schedule H medicines and Ayurvedic products classified as drugs under the Act. In practice, most Ayurvedic medicine distributors who require a wholesale drug licence will apply under Form 21B. However, if the product portfolio includes both Ayurvedic products and any Schedule C or C1 products — such as certain herbal injectables or biological preparations — a separate Form 20B licence may also be required. The applicable form should be confirmed with the State Drug Control Authority at the time of application.
What does Good Storage Practice compliance require for a distributor's storage facility?
Good Storage Practice (GSP) compliance for an Ayurvedic medicine distributor's storage facility requires that the premises maintain the temperature and humidity conditions specified on each product's label or storage instructions throughout the year. In practical terms, this means a dry, clean, well-ventilated storage area that can maintain room temperature conditions — typically below 30 degrees Celsius — for standard products, with separate temperature-controlled storage for any products requiring refrigeration. The facility must have a designated quarantine area for goods pending quality inspection or returned from the market, a separate dispatch staging area, and shelving that keeps stock off the floor to prevent moisture absorption. Documentation requirements under GSP include a temperature and humidity log maintained daily, a stock register showing batch numbers and expiry dates, and a record of any goods damaged or destroyed. Drug inspectors assess GSP compliance during routine inspections and can issue an improvement notice or initiate licence suspension proceedings if significant deviations are found.
How often must a wholesale drug licence be renewed, and what happens if it lapses?
Wholesale drug licences under the Drugs and Cosmetics Act are typically issued for a period of five years and must be renewed before the expiry date. Many states require annual payment of a licence fee to keep the licence in good standing, even if the licence itself has a five-year validity. If a drug licence lapses — either because the renewal application was not submitted in time, the fee was not paid, or a licence condition such as the qualified person requirement was not maintained — the distributor cannot legally purchase, stock, or supply scheduled drug products until the licence is reinstated. A lapsed licence also creates a supply chain problem: the principal manufacturer cannot supply products to an unlicensed dealer without violating their own regulatory obligations. Reinstatement after a lapse typically requires a fresh application with a premises inspection, which can take several weeks. Tracking renewal dates and initiating the renewal process 90 days before expiry is the standard practice to avoid this risk.
What should a distributor expect during a drug inspector visit?
A drug inspector visit can be either a routine inspection or a follow-up to a complaint or market intelligence report. During a routine inspection, the drug inspector will typically verify that the licence is current and displayed at the premises, that the qualified person is present or that their appointment is documented, that storage conditions meet Good Storage Practice requirements, that the stock register is current and reconciles with physical inventory, that batch numbers and expiry dates are legible on all products in storage, and that no unlicenced or misbranded products are present in the premises. The inspector may draw samples for testing. Distributors should be able to produce their drug licence, the qualified person's registration certificate, purchase invoices for all stock in the premises, the stock register, and the temperature and humidity log without delay. Missing or incomplete records, expired licence or qualified person registration, or substandard storage conditions are the most common grounds for improvement notices or enforcement action during drug inspector visits.
Distribute a Portfolio Including 17 US Patents with Regulatory Clarity
XpoAura Distribution represents a portfolio including 17 US patents covering 14 Ayurvedic formulations, with 50 products across 5 categories available for B2B distribution. Distributor appointments come with manufacturer regulatory support — so you understand the licence requirements for the specific portfolio before committing to a territory.
Apply to Become a Distributor